FDA Clears Path for New Preeclampsia Risk Test
Published Date: 6/26/2026
Rule
Summary
The FDA is officially putting the test that predicts preeclampsia risk into a safer, easier-to-get category called Class II. This change helps make sure the test works well and is safe, while also making it simpler for patients to access this important health tool. The new rules took effect on June 26, 2026, but the classification has been in place since May 18, 2023, helping companies save time and money on approvals.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Preeclampsia Test Moved to Class II
The FDA has classified the prognostic test for development or progression of preeclampsia into Class II (special controls). The order is effective June 26, 2026, and the classification has been applicable since May 18, 2023, which FDA says will reduce regulatory burdens and enhance patient access to the test.
Manufacturers Must Meet Study Requirements
Companies that make this prognostic test must provide detailed documentation of clinical performance studies across multiple intended-use sites and broad U.S. demographics, analytical performance studies (precision, reproducibility, metrological accuracy, analytical specificity), and documentation of a practitioner training program. The device remains subject to premarket notification under section 510(k).
Creates Predicate Pathway for Future Tests
Because the device was classified into Class II via the De Novo process, it can serve as a predicate device, allowing future similar devices to use the less burdensome 510(k) process rather than De Novo or premarket approval. FDA notes this can reduce regulatory burdens for subsequent device sponsors.
Labeling Must Limit Clinical Use
Labeling must include study results and limiting statements that the test is an aid in risk assessment and not intended for diagnosis, hospital discharge decisions, delivery decisions, or to inform immediate treatment changes including medication or hospitalization. These limits define how clinicians may use test results in patient care.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19704, Robotically-Assisted Surgical Devices-Premarket Submissions; Draft Guidance for Industry and Food and Drug Administration Staff; Availability
The FDA just dropped a draft guide for companies making robot-assisted surgical devices, showing how to get their products approved before selling. If you’re in the biz, now’s the time to check it out and send your feedback by November 24, 2026. This guide aims to make the approval process clearer and smoother, potentially saving time and money down the road.
2026-19655, Jeffrey Thies: Final Debarment Order
Jeffrey Thies is banned for 10 years from importing any drugs into the U.S. because he was convicted of trafficking fake drugs. He didn’t respond to the FDA’s notice, so the ban started on September 25, 2026. He can apply to end the ban anytime, but until then, no drug imports for him!
Previous / Next Documents
Previous: 2026-12899, Medical Devices; General Hospital and Personal Use Devices; Classification of the Foam or Gel Chemical Sterilant/High Level Disinfectant
The FDA is officially putting foam or gel chemical sterilants and high-level disinfectants into Class II, meaning they’ll have special safety rules but fewer red tape hurdles. This change helps companies bring safer, innovative cleaning products to hospitals and homes faster, starting June 26, 2026. If you make or use these devices, expect smoother approvals and better access without extra costs or delays.
Next: 2026-12901, Medical Devices; Neurological Devices; Classification of the Computerized Behavioral Therapy Device for the Treatment of Fibromyalgia Symptoms
The FDA is officially classifying a computerized behavioral therapy device for fibromyalgia symptoms as a Class II device, meaning it meets safety and effectiveness standards with special controls. This change helps patients get easier access to this innovative treatment by reducing some regulatory hurdles. The new classification is effective June 26, 2026, and could speed up how quickly these devices reach the market without extra costs.